Market Intelligence, Clinical Progress, and High-Purity Reagents for Mutant IDH1 Targeted Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for mIDH1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Mutant Protein (mIDH1 R132H/C/G/S/L) | Full-length / Catalytic domain. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 expressed. Theoretical MW confirmed. | View mIDH1 Products |
| WT IDH1 Recombinant Protein (Counter-screen) | For selectivity assays. High purity, enzymatically active. Endotoxin controlled. Critical for mutant vs. wild-type discrimination. | View IDH1 Products |
| mIDH2 Mutant Protein (R140Q/R172K) | Parallel mitochondrial isoform for cross-selectivity and resistance mechanism studies. High purity (>95%). | View IDH2 Products |
| Gene Delivery (Lentivirus) | mIDH1 Promise-ORF / Lentivirus. Full-length R132H ORF for stable cell line construction and cellular 2-HG production assays. | View mIDH1 Products |
| Benchmark Antibody (Anti-mIDH1 R132H) | Recombinant positive control. Sequence verified. Mutant-specific detection standard for ELISA/IHC. | View mIDH1 Products |
| Validator (siRNA Set) | mIDH1 siRNA Set for knockdown verification and specificity checks in cell-based assays. | View mIDH1 Products |
Critical Assay Challenges & Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs. WT Selectivity (Small Molecule Screening) | Matched Human WT IDH1 and mIDH1 (R132H/C/G/S/L) panel; >95% purity; Sequence Verified; Essential for accurate IC50 determination. |
| Cross-Isoform Selectivity (IDH1 vs. IDH2) | Human mIDH2 (R140Q, R172K) mutant proteins available for orthogonal counter-screening to avoid off-target effects. |
| Cellular D-2-HG Output Assay | mIDH1 Lentivirus for stable transduction; enables quantitative metabolite readouts (LC-MS or fluorescence-based). |
| Target Engagement & Specificity Controls | Anti-mIDH1 R132H Benchmark Antibody (IHC-grade) and validated siRNA included for on-target confirmation and background reduction. |
Live mIDH1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The mIDH1 inhibitor landscape has transitioned from first-in-class validation to next-generation optimization. With Ivosidenib established in AML and cholangiocarcinoma, and Vorasidenib recently approved for low-grade glioma, the field is now prioritizing CNS-penetrant scaffolds, rational combinations with hypomethylating agents and BCL-2 inhibitors, and mechanistic strategies to overcome acquired resistance at the R132 hotspot and allosteric sites. Emerging modalities such as antibody-drug conjugates (ADCs) and vaccine/immunotherapy approaches are also being explored for mutant-specific cytotoxicity and immune activation in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Servier/Agios (Ivosidenib, Vorasidenib), Novartis, Rigel, Forma Therapeutics | AML, Cholangiocarcinoma, Low-Grade Glioma | Mutant vs. WT Selectivity Assay (Need mutant & WT protein pair) |
| Brain-Penetrant Inhibitor | Agios, Forma Therapeutics | Glioma | Enzyme Kinetic Assay with CNS PK/PD profiling (Need sequence-verified R132H antigen) |
| ADC | Daiichi Sankyo (DS-1402a) | Glioma (mIDH1 positive) | Internalization + Epitope specificity (Need R132H-specific antibody) |
| Combination Therapy | Servier, Academic Centers | MDS, Glioblastoma | Cell-based D-2-HG Suppression Assay (Need lentivirus-stable lines) |
| Targeted Protein Degrader (PROTAC) | Emerging Biotechs | Solid Tumors, Resistant AML | Cellular Depletion Assay (Need high-purity mutant protein for ternary complex formation) |
| Vaccine/Immunotherapy | Immunocore, Academic Institutions | Solid Tumors | Antigen presentation assays (Need mIDH1 peptides and mutant protein) |